# Spruce Biosciences Presents MPS IIIB Data at CNS Meeting

> Spruce Biosciences to share natural history study results for MPS IIIB at Child Neurology Society meeting.
- Title: Spruce Biosciences Presents MPS IIIB Data at CNS Meeting
- Summary: Spruce Biosciences to share natural history study results for MPS IIIB at Child Neurology Society meeting. Spruce Biosciences will present natural history…
- Keywords: spruce biosciences, mps iiib, child neurology society, natural history study, enzyme replacement therapy, neurological disorders, breakthrough therapy, money, business, Spruce, Biosciences, Presents
- Source: Financialpost — https://financialpost.com/pmn/business-wire-news-releases-pmn/spruce-biosciences-announces-presentation-of-mps-iiib-natural-history-data-at-the-55th-child-neurology-society-annual-meeting
- Read time: 1 min
- Topics: spruce biosciences, mps iiib, child neurology society, natural history study, enzyme replacement therapy, neurological disorders, breakthrough therapy, money, business
## Spruce Biosciences Announces Data Presentation
Spruce Biosciences, a late-stage biopharmaceutical company focused on neurological disorders with unmet medical need, will present natural history data for MPS IIIB at the 55th Child Neurology Society Annual Meeting.
## Study 250-902 Details
Study 250-902, a prospective multicenter multinational noninterventional longitudinal natural history study, characterizes disease progression in pediatric participants with severe non-attenuated Sanfilippo Syndrome Type B.
## Presentation Schedule
The poster presentation occurs October 15, 2026, from 12:30 p.m. to 1:45 p.m. EDT and 5:30 p.m. to 7:30 p.m. EDT at the Child Neurology Society Annual Meeting in Montréal, Québec, Canada.
## Presenters and Authors
Ilyas Okur, M.D., Professor of Pediatrics at Gazi University Faculty of Medicine in Ankara, Türkiye, will present the study with a team of authors including Fatih Ezgu, M.D., Yin-Hsiu Chien, M.D., Ph.D., and others.
## Spruce Biosciences Focus
Spruce Biosciences develops tralesinidase alfa enzyme replacement therapy (TA-ERT) for MPS IIIB, a pediatric neurodegenerative disorder with no FDA-approved treatments.
## Regulatory Designations
TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation, and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation in the European Union.
## Key takeaway

Spruce Biosciences will present natural history data for MPS IIIB at the 55th Child Neurology Society Annual Meeting in October 2026.